Pfizer ( Pfizer )


Pfizer's picture

About Pfizer

Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.

We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.

Pfizer press release, blog etc

10/09/2018 - 07:57 Pfizer Announces Executive Leadership Team
09/20/2018 - 12:35 Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
09/17/2018 - 20:06 New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting
09/14/2018 - 21:27 Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress
09/05/2018 - 11:42 Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata
08/30/2018 - 14:17 Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy
08/27/2018 - 12:40 Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018
08/22/2018 - 10:50 Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
08/01/2018 - 10:35 XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis
07/31/2018 - 09:05 Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA (trastuzumab)
07/24/2018 - 14:28 Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs
07/20/2018 - 02:57 U.S. FDA Approves Pfizers Biosimilar NIVESTYM (filgrastim-aafi)
07/16/2018 - 16:27 Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
07/13/2018 - 15:22 U.S. FDA Approves XTANDI (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
07/11/2018 - 18:01 Pfizer to Organize for Future Growth
06/27/2018 - 21:08 XELJANZ (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis
06/27/2018 - 01:30 U.S. FDA Grants Priority Review for Pfizers New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
06/25/2018 - 01:42 Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE (Palbociclib) in HR+, HER2- Metastatic Breast Cancer